Archive for May, 2020

Predictive Genetic Testing and Consumer/Wellness Genomics Market: Snapshot

Genetic testing comprises examination of ones DNA. The term DNA refers to the chemical database that is responsible for conveying the instructions for functions that need to be performed by the body. Genetic testing is capable of revealing changes or mutations in the genes of living beings, which might result in any kind of disease or illness in the body.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1274

Predictive genetic testingrefers to the utilization of genetic testing methods in an asymptomatic individual to make a prediction about risk of contacting particular disease in future. These tests are regarded as representation of emerging class of medical tests, which differ in fundamental ways from the usual diagnostic tests.

The global predictive genetic testing and consumer/wellness genomics marketis likely to gather momentum owing to the benefits offered by predictive genetic testing.

The benefits of predictive genetic testing are

The global predictive genetic testing and consumer/wellness genomics marketis influenced by reducing cost of genetic sequencing and technological advancement in the field of genetics. North America is expected to emerge as a prominent region for the global predictive genetic testing and consumer/wellness genomics market in years to come due to high adoption rates of latest technologies in all fields.

Over centauries human DNA has undergone tremendous alteration due to evolutionary and lifestyle changes. They have led to both, advantages and disadvantages over the years. Some have given the mankind a deserving edge over other creatures while the others have led to disorders and diseases. Predictive genetic testing and consumer/wellness genomics market thrives on the growing demand for understanding the lineage of a certain gene pool to identify disorders that could manifest in the later or early stage of a human life. The surging demand for understanding the family history or studying the nature of certain diseases has given the global market for predictive genetic testing and consumer/wellness genomics market adequate fodder for growth in the past few years.

This new class of medical tests are aimed at reducing the risk of morbidity and mortality amongst consumers. The thorough surveillance and screening of a certain gene pool can allow an individual to avoid conditions that disrupt normal existence through preventive measures. The clinical utility of these tests remains unassessed. Therefore, increasing research and development by pharmaceutical companies to develop new drugs by understanding diseases and disorders is expected to favor market growth.

Unlike conventional diagnostic testing, predictive genetic testing identifies the risk associated with potential conditions. In certain cases it is also capable of stating when the disease may appear and the how severe will it be. Thus, this form of testing is expected to allow consumers to take up wellness measurements well in time to lead a life of normalcy, characterized by good health.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1274<ype=S

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Overview

Predictive genetic testing are used to identify gene mutations pertaining to the disorders that surface at a considerably later stage in life after birth. These tests are particularly beneficial for people from a family with a history of genetic disorder, although they themselves show no symptoms of the disorder at the time of testing. Genetic testing promises to revolutionize the healthcare sector, providing crucial diagnostic details related to diverse verticals such as heart disease, autism, and cancer. As the healthcare sector touches new peaks, the global predictive genetic testing and consumer/wellness genomics market is projected to expand at a healthy growth rate during the forecast period of 2017 to 2025.

This report on the global market for predictive genetic testing and consumer/wellness genomics analyzes all the important factors that may influence the demand in the near future and forecasts the condition of the market until 2025. It has been created using proven research methodologies such as SWOT analysis and Porters five forces. One of the key aspect of the report is the section on company profiles, wherein several leading players have been estimated for their market share and analyzed for their geographical presence, product portfolio, and recent strategic developments such as mergers, acquisitions, and collaborations.

The global predictive genetic testing and consumer/wellness genomics market, on the basis of test type, can be segmented into predictive testing, consumer genomics, and wellness genetics. The segment of predictive testing can be sub-segmented into genetic susceptibility test, predictive diagnostics, and population screening programs, whereas the segment of wellness genetics can be further divided into nutria genetics, skin and metabolism genetics, and others.

By application, the market can be segmented into breast and ovarian cancer screening, cardiovascular screening, diabetic screening and monitoring, colon cancer screening, Parkinsons or Alzheimers disease, urologic screening or prostate cancer screening, orthopedic and musculoskeletal screening, and other cancer screening. Geographically, the report studies the opportunities available in regions such as Asia Pacific, Europe, North America, and the Middle East and Africa.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Trends and Opportunities

Increasing number of novel partnership models, rapidly decreasing cost of genetic sequencing, and introduction of fragmented point-solutions across the genomics value chain as well as technological advancements in cloud computing and data integration are some of the key factors driving the market. On the other hand, the absence of well-defined regulatory framework, low adoption rate, and ethical concerns regarding the implementation, are expected to hinder the growth rate during the forecast period. Each of these factors have been analyzed in the report and their respective impacts have been anticipated.

Currently, the segment of predictive genetic cardiovascular screening accounts for the maximum demand, and increased investments in the field is expected to maintain it as most lucrative segment. On the other hand, more than 70 companies are currently engaged in nutrigenomics, which is expected to further expand the market.

Global Predictive Genetic Testing and Consumer/Wellness Genomics Market: Regional Outlook

Owing to robust healthcare infrastructure, prevalence of cardiovascular diseases, and high adoptability rate of new technology makes North America the most lucrative region, with most of the demand coming from the country of the U.S. and Canada. Several U.S. companies hold patents, which further extends the outreach of the market in the region of North America.

Companies mentioned in the research report

23andMe, Inc, BGI, Genesis Genetics, Illumina, Inc, Myriad Genetics, Inc, Pathway Genomics, Color Genomics Inc., and ARUP Laboratories are some of the key companies currently operating in global predictive genetic testing and consumer/wellness genomics market. Various forms of strategic partnerships with operating company and smaller vendors with novel ideas helps these leading players maintain their position in the market.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1274

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more:
Predictive Genetic Testing and Consumer/Wellness Genomics Market Estimated to Experience a Hike in Growth by 2025 - Cole of Duty

Detailed Study on the Global Direct-Access Genetic Testing Market

A recent market study throws light on some of the leading factors that are likely to influence the growth of the Direct-Access Genetic Testing market in the upcoming decade. The well-researched market study touches upon the growth potential of various budding market players in the current Direct-Access Genetic Testing market landscape. Moreover, established players, stakeholders, and investors can leverage the data in the report to formulate effective growth strategies.

As per the report, the Direct-Access Genetic Testing market is forecasted to reach a value of ~US$XX by the end of 2029 and grow at a CAGR of ~XX% through the forecast period (2019-2029). The key dynamics of the Direct-Access Genetic Testing market including the drivers, restraints, opportunities, and trends are thoroughly analyzed in the presented report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601843&source=atm

The Research Aims to Addresses the Following Doubts Pertaining to the Direct-Access Genetic Testing Market

The report on the Direct-Access Genetic Testing market provides a birds eye view of the current proceeding within the Direct-Access Genetic Testing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Direct-Access Genetic Testing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Direct-Access Genetic Testing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601843&source=atm

Direct-Access Genetic Testing Market Segmentation

Competitive Landscape

The competitive landscape section of the report elaborates on the recent developments and innovations introduced by prominent players in the Direct-Access Genetic Testing market. The growth potential, revenue growth, product range, and pricing strategies of each market player in inspected in the report with precision.

End-use Industry Assessment

The report segments the Direct-Access Genetic Testing market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Direct-Access Genetic Testing in each end-use industry.

The key players covered in this study23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull Genomes

Market segment by Type, the product can be split intoDiagnostic ScreeningPGDRelationship testingMarket segment by Application, split intoOnlineOffline

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-Access Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-Access Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-Access Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601843&licType=S&source=atm

Essential Findings of the Direct-Access Genetic Testing Market Report:

See the original post:
Global trade impact of the Coronavirus Direct-Access Genetic Testing Market Size Overview, Top Companies, Inventive Trends and Forecast to 2029 - 3rd...

Photo: Contributed

Is the wealth of information about your individual health risks worth the anxiety of knowing?

DNA testing kits have made it possible to access previously unmined information about your health. As a huge advocate of preventative medicine, Ive explored the pros and cons of accessing this wealth of information to see whether your spit is worth the price tag and the consequences.

Firstly, what is it? Companies like 23andMe offer a home-based saliva collection kit you spit in the tube and send it to the lab. From there, your DNA is extracted from the spit and a process called genotyping analyses the DNA.

You then receive a report with your health predispositions (diseases you are more likely to get due to your genes) and your carrier status of certain diseases, such as cystic fibrosis.

The most obvious benefit of getting your DNA tested is identifying your personal health predispositions. For instance, the report might indicate youre at risk of getting type 2 diabetes, or heart disease. With this information, you can make changes to your lifestyle to help prevent these diseases from occurring, such as quitting smoking, drinking less caffeine or eating less sugar.

Despite these benefits, it is important to consider the emotional stress of receiving unfortunate results. Finding out you are at high risk of Alzheimers has a huge emotional impact on an individual and their family, especially as there is little you can do to prevent it.

Personally, I wouldnt want to know Im at high risk for a disease I cant do anything about I think the anxiety the knowledge would cause wouldnt be worth the information.

Its also important to note that genealogy results arent definitive. For instance, they may identify the gene that can cause high cholesterol, which in turn can increase the risk of heart disease. However, the test doesnt take into account any other personal or environmental factors, such as your diet, exercise and lifestyle. Without input from your own family doctor or a genetic counsellor, the results cannot be taken as gospel.

The uses of genealogy DNA databases extend beyond personal use for health and ancestry information, and this is the part where I begin to question the safety of using these kits. Although companies have rigorous privacy policies, they do still keep your DNA and information in a database in order to identify future clients that may be within your family tree.

This data is vulnerable to hackers, but also to police and immigration officials. The CBSA uses genealogy DNA testing in an immigration setting to ascertain a persons identity, such as the country they originate from.

From the uses we know about, to those yet to be found Im not sure I want my DNA in a database with unknown potential.

There are also important financial implications that accompany genetic testing, such as the fact that some insurance companies now say you must disclose any genetic risk information you are aware of, which can mean higher premiums for health, life and travel insurance.

Having mused over the idea for several weeks, with my mouse hovering over the Add to Cart button more than once, Ive decided genetic testing is not for me, for now. I personally dont think you should need a genetic test to tell you to live a healthier lifestyle to exercise more, eat more greens and get better sleep.

If its something youre thinking about, or have done, I would love to hear your thoughts on it. If not, take it from me get out for a cycle or a run, spend more time with your family and eat some broccoli with a smile on your face.

More here:
The benefits and the costs of home DNA tests - Health and Happiness - Castanet.net

SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Board to nine members. Additionally, Mr. Spiegelman was appointed to the audit committee of Myriads Board.

Mr. Spiegelman has served as a Chief Financial Officer in several diversified biotechnology companies spanning 30 years. He was most recently Executive Vice President and Chief Financial Officer of BioMarin Pharmaceuticals, Inc., a pharmaceutical company focused on development of first-in-class and best-in-class therapeutics for rare genetic diseases. Having retired from that position after eight years, Dan now serves on the board of Tizona Therapeutics, Inc., a private pharmaceutical company, and has previously served on a number of public and private biotech company boards.

We are excited to welcome Dan to the Myriad Board, said Louise Phanstiel, Chair of the Board of Myriad. Dan brings a deep understanding of the biotech industry along with strong finance, M&A and business development experience. His background of creating value and growing early stage as well as established companies will provide useful strategic insights in executing our global strategy for molecular diagnostics and precision medicine.

The Company also announced today that Director John T. Henderson, M.D. will retire from the board at the Companys Annual Meeting in December 2020. Dr. Henderson joined the Board of Myriad in 2004 and has served as Chair of the Board from April 2005 through March 2020.

It has been a privilege to play a part of Myriads journey in becoming a leader in providing trusted healthcare advice to patients and their physicians, said Henderson. I have treasured the opportunity to work with so many Myriad employees whose passion and dedication to pioneering best of class precision medicine is unsurpassed. I certainly look forward to the companys continued growth and success.

In commenting on Dr. Hendersons pending retirement, Louise Phanstiel said, The Board sincerely appreciates all of Johns many contributions to Myriad as a leader, a colleague and friend. John has led with integrity and caring about Myriads Vision and Mission. He will be deeply missed and we wish him all the best.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Lynparza is a registered trademark of AstraZeneca.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Mr. Spiegelman providing useful strategic insights in executing the Companys global strategy for molecular diagnostics and precision medicine; Dr. Henderson retiring from the board at the Companys Annual Meeting in December 2020; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read the original:
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. - GlobeNewswire

Global Predictive Genetic Testing market analysis forecast to 2025 is a specialized and in-depth study of the industry with a focus on the global market trend. The report aims to provide an overview of global Predictive Genetic Testing market with detailed market segmentation by solution, deployment type, application, vertical and geography. The global Predictive Genetic Testing market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

Adroit Market Research provides analysis and insights regarding on Predictive Genetic Testing market the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.

Adroit Market Research provides analysis and insights regarding on Predictive Genetic Testing market the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Get sample copy of Predictive Genetic Testing Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/1276

The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The Predictive Genetic Testing market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

In addition, the report categorizes Predictive Genetic Testing market according to type, application, related technology, end user, etc. to provide the data explored. It also includes comprehensive data related to specific financial and business terms, projected market growth, market strategy, etc. This market report offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the Global Predictive Genetic Testing Market.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

The research report on global Predictive Genetic Testing market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Predictive Genetic Testing market. This market study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

Key Highlights Questions of Predictive Genetic Testing Market:What will be the size of the global Predictive Genetic Testing market in 2025?Which product is expected to show the highest market growth?Which application is projected to gain a lions share of the global Predictive Genetic Testing market?Which region is foretold to create the most number of opportunities in the global Predictive Genetic Testing market?Will there be any changes in market competition during the forecast period?Which are the top players currently operating in the global Predictive Genetic Testing market?

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See the article here:
Global Predictive Genetic Testing Market 2020: Type & Application, Innovation, Technology, Top Key Players, Regions & Forecast till 2025 -...

The report on the Newborn and Prenatal Genetic Testing market provides a birds eye view of the current proceeding within the Newborn and Prenatal Genetic Testing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Newborn and Prenatal Genetic Testing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Newborn and Prenatal Genetic Testing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Newborn and Prenatal Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Newborn and Prenatal Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2657649&source=atm

The major players profiled in this Newborn and Prenatal Genetic Testing market report include:

The key players covered in this studyPerkin ElmerVerinata HealthSequenom, Inc.Agilent Technologies, Inc.Bio-Rad Laboratories, Inc.Natera, Inc.Illumina, Inc.Ariosa DiagnosticsBGICapitalBio MedLab

Market segment by Type, the product can be split intoPCRFISHaCGHNIPTMSSMarket segment by Application, split intoHospitalClinicOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Newborn and Prenatal Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Newborn and Prenatal Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Newborn and Prenatal Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2657649&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2657649&source=atm

Continue reading here:
Impact of COVID-19 Outbreak on Newborn and Prenatal Genetic Testing Market Analysis 2019 Growth by Top Companies and Trends by Types, Treatment,...

UPDATE: (2:53 p.m. PT) Health officials in Clark County announced Tuesday that 84 people have tested positive for COVID-19 as part of an outbreak at a Vancouver fruit processor, Firestone Pacific Foods.

Sixty-nine employees have tested positive for COVID-19, four of whom arent Clark County residents. Another 15 people identified as close contacts of those cases have also testedpositive.

A total of 165 employees and 83 close contacts have been tested, with additional testing of employees and close contactsexpected.

The outbreak prompted Washington to pause Clark Countys request to move to Washingtons Phase 2 of reopening. It may be the largest non-health care-linked cluster of coronavirus cases in the greater Portland metroarea.

In total, 510 people have tested positive in Clark County and 25 people havedied.

The most recent available data from the Washington Department of Health show 19,265 confirmed coronavirus cases in the state and 1,050 knowndeaths.

The Oregon Health Authority reported 18 new coronavirus cases and one presumptive case in the state Tuesday. The states total number of known positive and presumptive cases is3,967.

Presumptive cases are people who have not tested positive but have COVID-19 symptoms and have had close contact with someone confirmed to be infected with thevirus.

Officials have reported no new coronavirus-related deaths for the second day in arow.

In Oregon, 148 people are known to have died fromCOVID-19.

Due to data reconciliation, one case originally reported as presumptive in Josephine County was determined to not be a case. Two other cases one in the 30-39 age group and one in the 70-79 age group were also determined not to becases.

Researchers at Oregon State University will look into Bends sewer system for genetic evidence of COVID-19 in an effort to help determine the virus prevalence in thecity.

Bend public works staff will collect sewage samples the weekend of May 30-31 as part of its Coronavirus Sewer Surveillance, the same weekend field workers from OSUs TRACE-COVID-19 project will gather nasal swab samples door-to-door inBend.

Sewer analysis results will be compared with nasal swab results to better detect the virus among symptomatic and asymptomatic carriers ofCOVID-19.

A really important step is to continue to validate the reliability of our sewer surveillance data with more traditional prevalence data from the medical community andresearchers.

Fortunately, the early indications suggest that sewer analysis is a reliable method, said Tyler Radniecki, an associate professor of environmental engineering said in astatement.

OSU said it has the lab capability to do genetic testing with a predicted turnaround time of about aweek.

The university said additional sewer surveillance projects are underway in WashingtonCounty.

In a three-sentence response to the Oregon Supreme Court, the Baker County Circuit Court Judge who vacated more than 20 of Gov. Kate Browns executive orders surrounding the states response to the coronavirus pandemic, told the court on Tuesday he wouldnt back down fromhisdecision.

I have elected to stand by my original ruling, Circuit Court Judge Matthew Shirtcliff wrote. I will not be vacating the May 18, 2020 Order Granting Preliminary Injunctive Relief and Denying Motions To Dismiss or takingotheraction.

A group of churches and eastern Oregon public officials have sued, arguing Browns executive orders exceed her authority understatelaw.

As Oregon counties continue to move forward with reopening, Portland International Airport has seen a small increase in travelers over the last twoweeks.

As states (and even other countries) begin to reopen, we expect the trends to continue slowly upward for air travel, said communications manager Susie Rantz with the Port ofPortland.

However, the virus is really in charge when it comes to air travel so its so hard to know what a few months from now might looklike.

Rantz said that passenger volumes at PDX are still down approximately 92% compared to this time last year. That decrease reached a bottom of nearly 96% inmid-April.

Airlines typically release their flight schedules on a quarterly basis, which saw dramatic reductions between April and June. Rantz said that passenger trends will become clearer when airlines update their Julyschedules.

The Oregon Employment Department announced Project Focus 100 on Tuesday, outlining a plan to address the 38,000 backlogged unemployment claims in the state.The department said it will continue to hire and train new employees, as well as assign experienced professionals on the oldest and most complexcases.

From May 29 to June 12, the agency said it will increase its outbound calls to resolve claims for people who have been waiting thelongest.

The Employment Department said it is trying out new ways of contacting people to let them know where their claims are in the system and said theyve identified ways to move claims out of processing traps that can delaythem.

See the article here:
84 Positive COVID-19 Cases Linked to Vancouver Fruit Processor - OPB News

Global Point-of-Care Genetic Testing Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

According to the current market situation, this report continuously observing promising growth of the global Point-of-Care Genetic Testing market. The report further suggests market appears to progress at an accelerating rate over the forecast period. Also, the major players are elaborated on the basis of the proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, report also examines R&D developments, legal policies, and strategies of Point-of-Care Genetic Testing market players.

Leading companies reviewed in the Point-of-Care Genetic Testing Market report are:Abbott (US)Roche (Switzerland)Thermo Fisher Scientific (US)Cepheid (US)IQuum (US)Biocartis (Switzerland)Idaho Technologies (US)Optigene (UK)Lumora (UK)

Get Free Sample PDF (including full TOC, Tables and Figures) of Point-of-Care Genetic Testing Market @ https://www.glamresearch.com/report/global-point-of-care-genetic-testing-market-by-323536/#sample

Global Point-of-Care Genetic Testing Market Split by Product Type and Applications:On the basis of Types:

POCT Cancer KitsMolecular POC KitsPOCT In Antibiotic TherapiesAssay CartridgeOther

On the basis of Application:

Diagnostic LabsBio-Pharmaceutical IndustryAcademic InstitutionsOther

The latest research on the Point-of-Care Genetic Testing Market fundamentally delivers insights that can empower stakeholders, business owners, and field marketing executives to make effective investment decisions driven by facts and extremely thorough research. The study aims to provide an evaluation and deliver essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the Point-of-Care Genetic Testing Market for the forecast period, 20202027. To help firms comprehend the Point-of-Care Genetic Testing industry in multiple ways, the report exhaustively assesses the share, size, and growth rate of the business worldwide.

Market, By regions:

Place Inquiry for Buying or Customization of Report: https://www.glamresearch.com/report/global-point-of-care-genetic-testing-market-by-323536/#inquiry

Report Highlights:

What Point-of-Care Genetic Testing Market Research Report Offers?

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Survey, Drivers, Restraints and Good fortune, Segmentation overviewChapter 2: Market competitiveness by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Overall profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Supply Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Influence Factors AnalysisChapter 12: Market PredictChapter 13: Point-of-Care Genetic Testing Research Findings and Conclusion, Appendix, methodology and data source

Access Full Report, here: https://www.glamresearch.com/report/global-point-of-care-genetic-testing-market-by-323536/

Read the original here:
Impact of Covid-19 Global Point-of-Care Genetic Testing Market (2020 To 2027) | Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US),...

The Global Genetic Testing Market 2020 industry Research Report will provide a valuable insight with an emphasis on global market. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/1608251

This report contains the major manufacturers analysis of the global Genetic Testing industry. By understanding the operations of these manufacturers (sales volume, revenue, sales price and gross margin from 2015 to 2020), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.

Key STRATEGIC MANUFACTURERS include in this report:-

GeneDx

Invitae

Pathway Genomics

Counsyl Inc

Asper Biotech

GenePlanet

Courtagen Life Sciences

Gene By Gene

Natera Inc

Regulatory

GeneTests

United Gene

HI Gene

Berry Genomics

23andMe Inc

360Jiyin

Novogene

CapitalBio

Agen

Biomedlab

Development policies and plans are discussed as well as growth rate, manufacturing processes, economic growth and worldwide strategies are analyzed. This Genetic Testing Research Report also states import/export data, industry supply and consumption figures as well as cost structure, price, industry revenue and gross margin by regions.

This report studies the Genetic Testing market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Genetic Testing industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Genetic Testing industry.

Global Genetic Testing market: types and end industries analysis

The research report includes specific segments such as end industries and product types of Genetic Testing. The report provides market size (sales volume and revenue) for each type and end industry from 2015 to 2020. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Genetic Testing market: regional analysis

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of Genetic Testing in these countries from 2015 to 2020, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.

Key Product Type Newborn Screening Diagnostic Testing Carrier Testing Preimplantation Genetic Diagnosis Prenatal Diagnosis Predictive and Presymptomatic Testing Pharmacogenomics Market by Application Cardiology Dermatology Hematology Hereditary Cancer Immunology Metabolic Disorders and Newborn Screening Neurology Ophthalmology Pediatric Genetics Others

Order a Copy of Global Genetic Testing Market Report @ https://www.orianresearch.com/checkout/1608251

Finally, the Report provides detailed profile and data information analysis of leading companies.

Major Points from Table of Contents-

1 Industry Overview of Genetic Testing

2 Major Manufacturers Analysis of Genetic Testing Industry

3 Global Genetic Testing Market Analysis by Regions, Manufacturers, Types and End Users

4 North America Genetic Testing Market Analysis by Countries, Types and End Users

5 Europe Genetic Testing Market Analysis by Countries, Types and End Users

6 Asia Pacific Genetic Testing Market Analysis by Countries, Types and End Users

7 Latin America Genetic Testing Market Analysis by Countries, Types and End Users

8 Middle East & Africa Genetic Testing Market Analysis by Countries, Types and End Users

9 Marketing Channel, Distributors and Traders Analysis

10 Global Genetic Testing Market Forecast by Regions, Countries, Manufacturers, Types and End Users

11 Industry Chain Analysis of Genetic Testing

12 Genetic Testing New Project Investment Feasibility Analysis

13 Genetic Testing Research Findings and Conclusion

14 Appendix

Note: We can also customize this record and provide individual chapters or a region-wise breakdown record such as North America, Europe or Asia. Also, if you have any special requirements, please let us know and we will offer you the record as you want.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence records on the World Wide Web. Our records repository boasts of over 500000+ industry and country research from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:-

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

See more here:
Genetic Testing Industry 2020 Market Detailed by Size, Share, Growth, Revenue, Companies Analysis and Forecast Research Report 2026 - Cole of Duty

New Jersey, United States, The Direct-To-Consumer (DTC) Genetic Testing Market report examines the market situation and prospects and represents the size of the Direct-To-Consumer (DTC) Genetic Testing market (value and volume) and the share by company, type, application and region. The general trends and opportunities of Direct-To-Consumer (DTC) Genetic Testing are also taken into account when examining the Direct-To-Consumer (DTC) Genetic Testing industry. Direct-To-Consumer (DTC) Genetic Testing The market report focuses on the following section: Analysis of the Direct-To-Consumer (DTC) Genetic Testing industry by transfer into different segments; the main types of products that fall within the scope of the report.

This Direct-To-Consumer (DTC) Genetic Testing market report is a complete analysis of the Direct-To-Consumer (DTC) Genetic Testing market based on an in-depth primary and secondary analysis. The scope of the Direct-To-Consumer (DTC) Genetic Testing market report includes global and regional sales, product consumption in terms of volume and value. The Direct-To-Consumer (DTC) Genetic Testing market report contains an estimate of revenue, CAGR and total revenue. The knowledge gathered in world trade Direct-To-Consumer (DTC) Genetic Testing is presented in figures, tables, pie charts and graphics.

Get | Research Sample Copy By Using Corporate Mail ID @https://www.verifiedmarketresearch.com/download-sample/?rid=25584&utm_source=COD&utm_medium=007

Top 10 Companies in the Global Direct-To-Consumer (DTC) Genetic Testing Market Research Report:

Global Direct-To-Consumer (DTC) Genetic Testing Market: Drivers and Restrains

The research report included analysis of various factors that increase market growth. These are trends, restrictions and drivers that change the market positively or negatively. This section also contains information on various segments and applications that may affect the market in the future. Detailed information is based on current trends and historical milestones. This section also includes an analysis of sales volume on the Direct-To-Consumer (DTC) Genetic Testing market and for each type from 2015 to 2026. This section mentions sales volume by region from 2015 to 2026. The price analysis is included in the report Type of year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020 and total price from 2015 to 2026.

An in-depth assessment of the restrictions contained in the report describes the contrast to the drivers and leaves room for strategic planning. The factors that overshadow the growth of the market are essential as they can be understood to design different phrases to take advantage of the lucrative opportunities that the growing Direct-To-Consumer (DTC) Genetic Testing market offers. In addition, information on the opinions of market experts was used to better understand the market.

Global Direct-To-Consumer (DTC) Genetic Testing Market: Segment Analysis

The research report contains certain segments such as application and product type. Each type provides revenue information for the 2015-2026 forecast period. The application segment also provides volume revenue and revenue for the 2015-2026 forecast period. Understanding the segments identifies the importance of the various factors that support Direct-To-Consumer (DTC) Genetic Testing market growth.

Global Direct-To-Consumer (DTC) Genetic Testing Market: Regional Analysis

The research report includes a detailed study of the regions of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Direct-To-Consumer (DTC) Genetic Testing report was compiled after various factors determining regional growth, such as the economic, environmental, social, technological and political status of the region concerned, were observed and examined. Analysts examined sales, sales, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2015 to 2026. These analyzes help the reader understand the potential value of investments in a particular region.

Global Direct-To-Consumer (DTC) Genetic Testing Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. It helps the reader understand the strategies and collaborations that players focus on to fight competition in the market. The full report provides a significant microscopic overview of the Direct-To-Consumer (DTC) Genetic Testing market. Readers can identify manufacturers footprints by knowing manufacturers global earnings, manufacturers world market prices, and manufacturers sales for the 2015-2019 forecast period.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584&utm_source=COD&utm_medium=007

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market, By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market, By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market, By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/Direct-To-Consumer-DTC-Genetic-Testing-Market/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read this article:
Direct-To-Consumer (DTC) Genetic Testing Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 -...

In 2029, the Predictive Genetic Testing And Consumer/Wellness Genomics market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Predictive Genetic Testing And Consumer/Wellness Genomics market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Predictive Genetic Testing And Consumer/Wellness Genomics market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Predictive Genetic Testing And Consumer/Wellness Genomics market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

The report on the Predictive Genetic Testing And Consumer/Wellness Genomics market provides a birds eye view of the current proceeding within the Predictive Genetic Testing And Consumer/Wellness Genomics market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Predictive Genetic Testing And Consumer/Wellness Genomics market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2675622&source=atm

Global Predictive Genetic Testing And Consumer/Wellness Genomics market report on the basis of market players

The report examines each Predictive Genetic Testing And Consumer/Wellness Genomics market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Predictive Genetic Testing And Consumer/Wellness Genomics market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Key market playersMajor competitors identified in this market include Illumina, BGI, Genesis Genetics, Myriad Genetics, 23andMe, Inc, Color Genomics Inc, Pathway Genomics, ARUP Laboratories, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:Predictive TestingConsumer GenomicsWellness Genomics

Based on the Application:Breast & Ovarian CancerCardiovascular screeningDiabetic Screening & MonitoringColon CancerOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2675622&source=atm

The Predictive Genetic Testing And Consumer/Wellness Genomics market report answers the following queries:

The Predictive Genetic Testing And Consumer/Wellness Genomics market report provides the below-mentioned information:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2675622&licType=S&source=atm

Research Methodology of Predictive Genetic Testing And Consumer/Wellness Genomics Market Report

The global Predictive Genetic Testing And Consumer/Wellness Genomics market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Predictive Genetic Testing And Consumer/Wellness Genomics market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Predictive Genetic Testing And Consumer/Wellness Genomics market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Go here to read the rest:
Potential Impact of COVID-19 on Predictive Genetic Testing And Consumer/Wellness Genomics Market Analyzed in a New Intelligence Study - Bulletin Line

Global Predictive Genetic Testing market research report provides details on key factors such as drivers, opportunities and trends expected to have a major impact on the market during the forecast period 2020-2025. It also highlights such information. Expansion and growth rates to help business owners and manufacturers plan strategies to smoothly achieve their goals in the near future. Researchers have thoroughly researched historical markets to provide insights into current market scenarios and to help companies get more information.

The given report is an excellent research study specially compiled to provide the latest insights into critical aspects of the Global Predictive Genetic Testing Market by Adroit Market Research with more market data pie charts, charts, statistics and graphs.

Get sample copy of Predictive Genetic Testing Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/1276

For future market growth, global keyword market forecasts have been observed with various macroeconomic factors and changing trends according to the markets future forecasts. Other important factors covered in the report include current market size, supply and demand side inputs, and other dynamics shaping market scenarios. Report forecasting is provided in CAGR and other important criteria such as annual growth and absolute dollar opportunities are also incorporated to provide clear insights and future opportunities.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

The Global Predictive Genetic Testing Market Report includes the top companies in the market, with company profile, growth aspects, opportunities and threats to market development. This report provides an industry analysis of the estimated time scale. This report covers the latest industry details related to industry reports, import and export scenarios and market share. The report also included basic opinions on the market environment, emerging and high growth sectors of the market, high growth regions, market drivers, papermaking and market opportunities. This study aims to estimate the current market size and growth potential of the global keyword market in sections like applications and representatives.

Geographically, the Predictive Genetic Testing market report is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. This analysis report similarly reduces the present, past and in future market business strategies, company extent, development, share and estimate analysis having a place with the predicted circumstances. Moreover, the possible results and the exposure to the enhancement of Predictive Genetic Testing market widely covered in this report.

The report is answerable to the following questions:1. What are the major factors driving the market growth?2. What key advancements in the near future?3. Which are the latest modernizations in the Global Predictive Genetic Testing Market Research Report 2020-2025 Market by the key players?4. What are the crucial ongoing trends observed in the market?5. What factors are restraining the market growth?

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Continue reading here:
Predictive Genetic Testing Market 2020 Global Key Players, Trends, Share, Industry Size, Growth, Opportunities and Forecast to 2025 - News Distinct

An Italian teenager may be the first known case of a painful thyroid infection caused by the new coronavirus, doctors report.

A research team from Pisa, in northern Italy, said the 18-year-old woman's thyroid became sore and enlarged a few weeks after testing positive for the SARS-CoV-2 virus in late February. The condition, called thyroiditis, cleared up completely within a week after she was treated with the steroid prednisone.

Still, the doctors believe that "physicians should be alerted about the possibility of this additional clinical manifestation" tied to the new coronavirus, study leader Dr Francesco Latrofa, an endocrinologist at the University Hospital of Pisa, said in a news release from the Endocrine Society. He and his colleagues published the findings on 21 May in The Journal of Clinical Endocrinology & Metabolism.

"Covid-19 continues to show us many surprises," said thyroid expert Dr David Hiltzik, director of head and neck surgery at Staten Island University Hospital in New York City. "It has been shown to manifest in so many different organ systems throughout the body, so it is not surprising that the thyroid joins the many other areas that have been affected by the disease.

Heart palpitations and neck pain

"Thankfully, thyroiditis can easily be treated and should not be of great concern," added Hiltzik, who wasn't involved in the new research. "That being said, if a patient had the virus and presents with new neck pain they should get that evaluated."

In the Italian woman's case, she first got a nasal swab test for the new coronavirus on 28 February because her father had been hospitalised earlier with Covid-19. The test turned up positive, but she experienced only mild, transient respiratory symptoms at first.

However, by 17 March she revisited the Pisa clinic with fever, heart palpitations and neck pain. The neck pain got worse and her thyroid gland was painful and enlarged, the doctors said.

Tests confirmed thyroiditis. The patient was given prednisone, which relieved the neck pain and fever within two days. Any other remaining symptoms subsided within a week.

Post-viral thyroiditis

Latrofa and his group noted that thyroiditis has been seen with a myriad of infections, including mumps, Epstein-Barr, hepatitis E and HIV, so its appearance with SARS-CoV-2 isn't completely surprising. But to their knowledge, this is the first such case tied to the new coronavirus.

Dr Minisha Sood is an endocrinologist at Lenox Hill Hospital in New York City. Reading over the findings from Italy, she said it was "a classic presentation of post-viral thyroiditis, which is characterised by the onset of neck pain, fever and high thyroid hormone levels".

Sood said because of the intensity of neck pain the woman was experiencing, her doctors prescribed prednisone. However, in milder cases, a nonsteroidal anti-inflammatory pain reliever is often prescribed first, with a steroid prescribed later if needed.

In any case, "as an increasing number of post-viral symptoms are being attributed to Covid-19 or complications of Covid-19 such as thrombotic [clotting] events, the potential of subacute thyroiditis should not be overlooked," Sood said.

Image credit: Getty Images

See the rest here:
Coronavirus can infect and inflame the thyroid - Health24

I have always been tempted to write a prescription that reads Go out and play just to see how the parent responds.

Turns out, there is no better time than this nearly three months into the social distancing, no public gatherings and shelter-at-home requirements to prevent the spread of COVID-19 to follow that exact recommendation.

As a pediatrician in Kenner Army Health Clinic, I have observed how this situation has not been ideal for people in general. They have been affected physically, emotionally, socially and economically. For children, there is another vulnerable plane, developmentally.

Lately, I have encountered an unusual number of TeleHealth concerns related to emotional, behavioral and developmental regression in youngsters. It is troubling to imagine the coronavirus mutating into a dreadful boogeyman that inflicts children with these mental health issues.

Its simple to beat the monster, though, with play which is defined in a 2018 American Academy of Pediatrics article as an activity that is intrinsically motivated, and entails active engagement and results in joyful discovery.It is not scripted play therapy, but genuine family activity that brings forth positive emotions while promoting child development and growth.

The Pediatric Journal magazine article further reads, When play and safe, stable, nurturing relationships are missing in a childs life, toxic stress can disrupt the development of executive function and the learning of prosocial behavior. In the presence of childhood adversity, play becomes even more important.

The article points out that age-appropriate play with parents and peers is a singular opportunity to promote the social-emotional, cognitive, language and self-regulation skills that build executive function and a prosocial brain which children need to thrive.

Research among preschoolers on the first day of school showed a twofold decrease in anxiety in medical terms, a reduction in the stress hormone salivary cortisol when randomly assigned to play intervention compared to listening to a teacher reading a story.

Laboratory scientists also have simulated the role of roughand-tumble play and learned that it can buffer symptoms of anxiety in animals that similarly showed a reduction in stress hormone that could be prolonged by the length and intensity of the activity level. The researchers observed increased brain competency in the subjects, witnessing the ability to solve mazes after two hours compared to the play-deprived group.

With the ongoing challenges of the pandemic, caregivers may want to invest in more meaningful play time with children, and while doing so, may even find themselves unexpectedly rewarded. By recreating their cherished childhood activities or sharing a favorite game with youngsters, some grown-ups may benefit from this renewed joy through a childs view. This benefit also is supported by a research.

Organized daily playtime at home during this pandemic may seem tiring to already stressed-out parents, but the rewards are worth the investment. Spontaneity is welcomed in this area and may surprisingly bring more fun. Encouraging children to plan the activity is a good tool for self-growth. Parents are not asked to be activity directors. Play should not be a dreaded chore and should never add more stress. And like any medicine, it should not be overdosed responsible adults have to work and rest, and children need downtimes as well.

With studies consistently showing the superior benefits of real-time social playing among young children, some limited age-appropriate screen time with parents co-watching or co-playing can be an occasional alternative. Play needs adult supervision because it can have a dark side when children are allowed to do as they please, leading to disagreements and even bullying. Homes should always be safe and nurturing a play hideout from the coronavirus boogeyman.

Playing is important for everyones well-being, and especially for the development of a young healthy child. While peer-to-peer play is almost impossible due to social distancing, families must strive together, more than ever, to create nurturing physical connections through playtime now; because playing is a medical necessity for children to thrive.

Go here to see the original:
Play: A joyful medicine - Public Affairs Office of Headquarters, US Army Combined Arms Support Command and Fort Lee

HEALTH REASONS. KC Concepcion says she been diagnosed with polycystic ovary syndrome or PCOS, which has prevented her from accepting showbiz projects. Screenshot from Instagram/@itskcconcepcion

MANILA, Philippines Actress KC Concepcion said she had been scaling back in accepting showbiz projects after she was diagnosed with polycystic ovary syndrome or PCOS.

In an interview with Tim Yap on his online show on Saturday, May 23, KC was asked why she has not been seen on television or movies, despite signing with Cornerstone Entertainment back in February.

"I am super, super grateful for work. But number one... I want to be super open about this because its something I also want to talk about in the future. I was diagnosed with PCOS," she said.

PCOS, according to the Mayo Clinic, "is a hormonal disorder common among women of reproductive age" which results in "infrequent or prolonged menstrual periods or excess male hormone (androgen) levels."

The condition is the reason why she gained weight, she said.

"I always wanted to be at my best, I want to be physically fit, and I want to look good, I want to get my body tight. When I look good, I feel good and thats what you serve people on screen. Its as simple as that, she said.

While she was on break, KC said that she was able to work on a lot of things, including her jewelry line Avec Moi. She is also set to revive KC's Closet to pre-loved items for charity.

KC said that she's been getting a lot of guidance with her PCOS thanks to her doctor in the US. I know a lot of women who have it. Its quite common in a way but not a lot of people talk about it. Thats something I want to talk about in depth later on in the future na because I dont think right now is the time. Wala pa ako masyadong information about it, she said.

(I still don't have much information about it.)

KC said she now ready to accept projects coming her way. Im super healthy now. Im so well. I take supplements, try to be as active as I can be."

Relationship with mom Sharon

In the same interview, Tim asked if KC has been in contact with her mom, Sharon Cuneta, and her family. KC is currently living by herself in her apartment .

KC said they've been checking up on each and that they've been sending each other food.

"That's our way of expressing our love is through gifts. I think my mom and I have the same love language, where we like to give each other gifts. I miss her, I love her so much. I think she is an amazing mom. At the end of the day, lahat ng nangyayari sa amin should stay in the family and just like any family, no one is perfect, she said.

(At the end of the day, whatever is happening in our family should just stay within the family and just like any family, no is perfect.)

Back in January, Sharon wrote a long post on social media, asking KC to come back to the family. The actress was not present during some of their holiday gatherings and Sharon's birthday celebration on ASAP.

Sharon told the media that the post was a case of a "mother missing her daughter."

The two have since ironed things out, with Sharon promoting KC's YouTube account in March.

KC said that like any other family, their relationship has not been perfect.

I dont really like talking about problems in public but people love us and have really welcomed us in their lives. I want to thank everyone that is there to support my relationship with my mom. Every day, you just want everything to be nice and light and happy, " she said.

"If there was time lost before, I think the most important thing is to both embrace each others imperfections and forgive and be loving towards each other. Thats the best we can do, she said. Rappler.com

See the original post here:
KC Concepcion says PCOS prevented her from accepting projects - Rappler

Amy Sapien had prepared for her April 13 surgery as best she could. She dyed her long blond hair a bright pink. She got a tattoo on her right calf of what she jokingly calls her spirit animal Dory, the blue fish from Finding Nemo, whose answer to lifes challenges is to say, over and over, Just keep swimming. Still, she was overwhelmed by dread early that morning as she kissed her husband, Callen, goodbye outside the Moffitt Cancer Center in Tampa, Fla., and walked alone through the bright, empty lobby. Her hands shook as she stepped onto the elevator and pressed the button with her elbow.

Her mind was a jumble. Everyone seemed so eerily expressionless from behind their paper masks that Sapien wondered for a moment whether shed walked onto the set of an alien abduction movie. She had been imagining for weeks what it would be like to leave the hospital without her left breast. Now her mind turned to an even more urgent fear: What if she became infected with the coronavirus during her short stay?

Sapien tried to replace her anxious thoughts with fighting ones. The 40-year-old hospital social worker made Tom Pettys lyrics her mantra: You can stand me up at the gates of hell, she sang to herself as she felt her consciousness give way in the operating room. But I wont back down.

When she came to three hours later, she pushed aside her worries about the treatment and procedures she still faced, nibbled on Saltines, and sipped ginger ale to stave off the nausea she felt from anesthesia. Then she reached for her phone, and recorded separate video messages for her two young boys.

Her blue eyes glazed thick from painkillers, she addressed her 3-year-old son, Corben. Smiling reassuringly, she told him to continue his toilet training with his grandmother, and that shed be home soon. Then she spoke to 7-year-old Landen. Hey. Im OK. Im out of surgery, she said in a near-whisper. With her bandage peeking from her pink surgical robe, she told him that shed be home the next day, and that they would soon be able to watch movies together from the bedroom recliner. I love you, I dont want you to worry about me, Landen, she said. OK? Im doing really good. Bye, honey.

Then she tapped send. Landen watched the video from his own hospital room across town, where he was being treated for leukemia.

Amy and Landen, two generations fighting cancer, are united by something else: They are going through the most frightening and painful moments of their lives without the family warmth and support that was standard practice at the nations medical centers until Covid-19. The pandemics broad impact on cancer care in the U.S. is well-known: non-essential surgeries, biopsies, and scans delayed, and clinical trials disrupted. But its in stories like the Sapien familys that one sees the depth of the harm its causing.

Amy was able to schedule the mastectomy right away only because her cancer was spreading, but she couldnt have her second breast removed at the same time since it was deemed elective. Instead shell have to undergo general anesthesia, surgery, and painful rehab again. While her husband was allowed in the waiting room during her first worrisome mammogram and ultrasound in early March, Amy had to go alone for her biopsy and the MRI that confirmed the diagnosis. Then she went by herself to her surgery, and recovered in isolation.

I didnt see anyone I knew for 36 hours after having a part of my body amputated, she said. Worse, though, was her inability to be with Landen as he lay tethered to a machine delivering a platelet transfusion.

While both parents, and sometimes his grandparents, had been able to reassure him through previous chemotherapy treatments, this time only his father could be present.

Theirs is an experience shared by cancer patients across the country, as Covid-19 separates them from loved ones and family at their time of greatest need.

In the exact moment where we could have reached out for everything our support system could offer, Amy said, we were forced to retract completely into ourselves.

It was last June, a few weeks before Landens seventh birthday, that his grandmother Sandra Sapien noticed a swollen gland on his slender neck. The family had just moved from a nearby town and had not yet met their new doctors, so Amy took Landen to a walk-in clinic to rule out strep. The test was negative, but the doctor suggested following up with a pediatrician and asked if there was a family history of leukemia. No, Amy said, alarmed. None at all.

Days later, at an appointment with Landens new pediatrician, Amy mentioned what the urgent-care doctor had said and asked if he could run some blood tests. Its never cancer, he told her. He diagnosed Landen with tonsillitis, and prescribed antibiotics. Landen seemed fine at his birthday party, and wolfed down pizza and the massive chocolate Minecraft cake his grandmother had made.

The morning of June 29, the family drove to a pet store to pick out a fish for Corben. As he deliberated among the bright blue and red beta fish, Landen turned gray and collapsed. Thinking that hed had a bad reaction to the antibiotics, Callen rushed him to the hospital.

In just a few hours, the couple went from worrying about whether rain would spoil that evenings fireworks to confronting every parents nightmare. After doctors ran a battery of tests, the Sapiens learned that their son was one of 350 to 525 U.S. children diagnosed with a rare form of leukemia each year. Overall, 3,500, or 4.7 out of 100,000, are diagnosed annually with childhood blood cancers.

Leukemia? Amy recalls asking, incredulous. My brain wasnt even linking up what the word was.

As a young woman, Amy had struggled with anxiety, but finally everything had fallen into place. She and Callen, 36, a strategist at a business software company, had solid, steady careers. Together since their first meeting at a college-town coffee shop 17 years ago, they had just purchased their dream home. Id finally convinced myself there were no monsters under my bed, she said.

Now the doctors were hospitalizing their son, and had begun a 3 1/2 year regimen of in- and outpatient chemotherapy treatments that during some stretches required daily infusions.

Callens mother and stepfather, colleagues, and friends rushed to help, providing lunches, dinners, even breakfasts, so the family could focus on Landen and managing his hospital schedule. Amys co-workers donated sick leave.

The couple tried to make life as normal as possible for Corben; both continued working, and resolved never to show their fear to their son. Nobody ever got a trophy for crying on the floor for three years, Amy said.

Early this winter, news of the pandemic began to percolate. Because Landens treatments impaired his immune system, he was at risk for opportunistic infections. The family had initiated a series of precautions: limiting visitors; carrying hand sanitizer; washing every item that came into their house. We were acting as if Covid existed before Covid existed, Callen said. We were already being hypervigilant.

One evening in mid-February, the whole family was gathered on the couples bed watching Ninjago. Amy was leaning against Callens arm, which had fallen asleep. When she wriggled away to release it, her left breast grazed his hand. In that split-second touch, he felt something unusual and hard. Whats that? he asked. Amy padded her breast with her fingertips, immediately detecting a small mass.

Her mother had had breast cancer, and her grandmother had died of the disease. But they had drank and smoked, lifestyle behaviors that increased their risk. Amy had had a baseline mammogram at 33, and had tested negative for the BRCA genes that dramatically increase the risk of breast cancer. I thought I had an insurance policy against having to go through this, she said.

When she turned 40 in October, her doctor had recommended that she get a second mammogram. But she had told herself she would schedule it until after Landen had completed his first year of treatment.

Now she feared the worst. Landens diagnosis had been improbable. Could the universe betray them twice? Im scared, she told Callen.

Landen, hypersensitive to any health news, looked up. Why?

Amy reigned herself in. I couldnt cry in front of him after watching him be poked and prodded hundreds of times and never complaining. Its not fair to expect a 7-year-old to do what I cant.

I couldnt cry in front of him after watching him be poked and prodded hundreds of times and never complaining.

She was sitting at her work desk when a nurse practitioner called her cellphone with the biopsy results: She had invasive lobular cancer. Amy tried to write down the diagnosis on the back of an envelope. The words went into my ears, but they just werent registering, she recalled. How do you spell that? she kept asking. She hung up and burst into tears. Its not fair, she said to her office mate, who was trying to console her. Were good people. It was supposed to be benign.

In those early weeks of the coronavirus, hospitals were just putting in place social distancing rules to protect patients from infection. Family members were prohibited or sharply limited from joining cancer patients as they go from diagnosis to surgery, from chemotherapy to recovery.

Suddenly, the Sapiens could no longer turn to their community for help either. Their kitchen, in disrepair after a massive leak, had only a working hot plate, but they couldnt accept meals. Amy, who has a well of close friends, couldnt see them on weekend lunch dates.

Cancer remains the second-leading cause of death in the U.S., and 1.8 million people are diagnosed annually. Many end up with plans of treatment that last for months, if not years, that require regular surveillance and lifesaving but immune-suppressing drugs.

In her job, Amy has worked with a series of vulnerable populations, from the homeless to veterans to the elderly. As she lurched alone from procedure to procedure at Moffitt, she of course understood that barring patients partners reduced the chance of infections by half. But she also knew that family members play an important role in making decisions about treatment. Its so hard to absorb what youre hearing when youre the patient, she said. That second pair of ears is so important in cancer treatment.

Meanwhile, St. Josephs Childrens Hospital, where Landen was being treated, issued similar restrictions. In the past, we allowed parents, grandparents, even siblings to accompany patients during treatment, said Don Eslin, Landens pediatric hematology oncologist. Now they can only have one parent.

As recently as February, he said, it was common for families whose children were being treated for blood cancers to share stories and encouragement in cafeterias and the waiting room.

Now that support is reduced to a wave from behind a mask down the hallway, Eslin said.

Doctors, too, saw their routines upended in unsettling ways. Eslin must sometimes deliver bad news by phone, something he has always striven to avoid. This is adding complexities to cancer care in a way we never imagined, he said.

Catherine Lee, Amys surgeon, feels most the loss of connection with patients. Since the third week of March, she has only been able to make eye contact with her patients at one of the most terrifying moments of their lives.

A breast cancer diagnosis is so intimate, Lee said. We always want our patients to feel that we are giving as much as we can to them in terms of support and compassion, and to reassure them that were doing as much as we can for them.

From behind her mask, she can only offer supportive words. They cant see my smile. I cant shake their hands, and I certainly cant give them a hug, she said.

In their brief meeting, Lee and Amy discussed Landens situation, and how Amy needed to be back on her feet as soon as possible.

As Lee reflected on the case during a FaceTime call, she paused for a moment: You know something? I dont even know what Amy Sapien looks like.

For the past seven weeks, she said, about the only thing I see of my patients is their breasts.

Amy is recuperating, working from home to help veterans navigate the Covid-19 crisis. She is never far from her sons, and tells them every day how lucky she feels to be their mother. Landen is now in maintenance therapy, and his doctors have replaced his grueling chemo infusions with an oral drug. Some days, his second grade teacher drops by, and they shout to each other through a closed window.

Earlier this month, she got the news that she wont need chemotherapy, but will be on hormone suppression treatments for at least the next decade, and will go into rapid menopause. It is highly likely that she will need a hysterectomy.

Still, she tries to focus on what she can control. She oversees Landens home schooling, which he does by Zoom with his teacher. She watches the boys as they make up imaginary games with their Duplos, and swim in the backyard pool when Landen is well enough. The family just got a new puppy, a brown Bernedoodle named River. The Sapiens had promised a party and a puppy as a way to mark the end of Landens infusions, and what they hoped would be the resumption of a more ordinary life. The puppy adds chaos but also normalcy.

Although Amy and Callen have tried to shield the children from the news, the pandemic is nonetheless a constant backdrop. Sometimes Landen wonders aloud about whether the virus could kill him or everyone in the family. And he worries about his mother, telling her recently that he hoped she wouldnt have to get an infusion port like his. Amy tries to reassure him.

I tell Landen being brave isnt not being scared, she said. Its being scared and doing it anyway.

Here is the original post:
Covid-19 isolates patients from loved ones at time of greatest need - STAT

The Blood Testing Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2026. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Blood Testing Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=79004

Key List Market Participants in the Market:Abbott LaboratoriesBio-Rad LaboratoriesF. Hoffmann La RocheSiemens Healthineers

By Types:GlucoseLipidBUNA1CCRPVitamin DALTASTThyroid Stimulating Hormone

By Applications:HospitalsClinic and Diagnostic CentersOthers

Scope of the Blood Testing Market Report:

Fill the Pre-order Inquiry Form for the Report @https://dataintelo.com/enquiry-before-buying/?reportId=79004

By Regions:North America (The USA, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of Europe)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa).

Report Answers Following Questions:

To Purchase This Report, Visit https://dataintelo.com/checkout/?reportId=79004

Blood Testing Market Historic Data (2015-2019):

Blood Testing Market Forecast (2020-2026):

To Get this Report at an Incredible Discounts, Visit @ https://dataintelo.com/ask-for-discount/?reportId=79004

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: sales@dataintelo.comWebsite: https://dataintelo.com

See the original post:
Blood Testing Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report... - Azizsalon News

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Endometriosis TherapiesMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Endometriosis Therapies Market Players to battle Covid-19 Impact.

The Endometriosis TherapiesMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Endometriosis Therapies market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Endometriosis Therapies market.

Top Leading players covered in the Endometriosis Therapies market report: AbbVie, EliLilly, AstraZeneca, Bayer, AstellasPharma, MeditrinaPharmaceuticals, Pfizer, NeurocrineBiosciences, TakedaPharmaceutical and More

Get PDF Sample Report With Impact of COVID-19 on Endometriosis Therapies [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/71231

The report offers clear guidelines for players to cement a position of strength in the global Endometriosis Therapies market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Endometriosis Therapies market will showcase a steadyCAGR in the forecast year 2020 to 2026.

Market Segment by Type covers:HormonalContraceptivesGonadotropin-releasingHormone(Gn-RH)AgonistsProgestinTherapyAromataseInhibitors

Market Segment by Application covers:HospitalClinicOther

Our Complimentary Sample Endometriosis Therapies market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/71231

Regions Covered in the Global Endometriosis Therapies Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Endometriosis Therapies Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Endometriosis Therapies market Exhaustive research on innovation and other trends of the global Endometriosis Therapies market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/71231/Endometriosis-Therapies-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/71231/Endometriosis-Therapies-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

Read this article:
Endometriosis Therapies Market Global Industry Outlook, Share, Growth Analysis, Trends and top manufacture like AbbVie, Eli Lilly, AstraZeneca,...

Doctors warn that taking high doses of Vitamin D has little or no effect on COVID-19, and they urge against taking more of the supplement than is recommended since it can have adverse health effects.

This update comes in the wake of people pounding down the D supplementsas a prophylactic measure, after learning that many patients with the worst symptoms and outcomesafter being diagnosed with COVID-19, have also been vitamin D deficient.

Countries, where COVID-19 cases have resulted in the highest death rates, are also those where more of the population has D deficiencies. Researchers across the globe have found thatthe sickest patients often have the lowest levels of vitamin D.These facts have led individuals who are not sick to start taking large doses of vitamin D.

There is a connection between vitamin D and respiratory illness, but that does not mean that overdosing is a healthy move. Expertsdo say that healthy blood levels ofvitamin Dmay give some protection against the worst symptoms if you do contractCOVID-19. One possible advantageis that vitamin D can help preventthe body from experiencing the so-called "cytokine storm," when the body'simmune systemoverreacts and attacks itsown cells and tissues, much like a histamine response to an allergen. But too much D is not beneficial.

In anew warning by doctors in the UK, researchers at Birmingham Universityare warning people to not overdose themselves with D to gain any potential benefits or edge against the virus. According to The Independent,a steady stream of patients are showing up at hospitalsin theUKhaving takentoxicdoses ofvitamin Dinsupplementsthey bought online. The pills that are poisoning them contain up to 2,250 times the recommended daily dose of D (which is 600 IU according to the Mayo Clinic) and this toxic level of D is putting patients at risk ofheartandkidneyproblems, according to theNHSlab, which said it sees two to three overdose cases every week.

Scientists from the UK, Europe and the US, including experts from the University of Birmingham, have published aconsensus paper warning against taking high doses of vitamin D supplementation.

According to the study,new research shows high levels of vitamin D provides little or no benefit in preventing or treating Covid-19. The study'sauthors advise that the population adhere to Public Health England guidance on supplementation.

Following unverified reports that high doses of vitamin D (higher than 4000IU/d) could reduce the risk of contracting COVID-19 and be used to successfully treat the virus, the new report published in the journal BMJ, Nutrition, Prevention and Health, investigated the current scientific evidence base on the vitamin and its use in treating infections.

Vitamin D is a hormone produced in the skin during exposure to sunlight and helps regulate the amount of calcium and phosphate in the body, which are needed to keep bones, teeth and muscles healthy.

Most of our vitamin D comes from exposure to sunlight, however for many people, particularly those who are self-isolating with limited access to sunlight during the current pandemic, getting enough vitamin D may be a real challenge. Supplementing with vitamin D ... should be done under the current UK guidance," saidProfessor Carolyn Greig, a co-author of the paper, also from the University of Birmingham.

Professor Judy Buttriss, Director General British Nutrition Foundation and a co-author of theresearch said: In line with the latest... guidance on vitamin D, we recommend that people consider taking a vitamin D supplement of 10 micrograms a day during the winter months (from October to March), and all year round if their time outside is limited.

Although there is some evidence that low vitamin D is associated with acute respiratory tract infections, there is currently insufficient evidence for vitamin D as a treatment for COVID-19 and over-supplementing must be avoided as it could be harmful.

Examining previous studies in this field, the scientists found no evidence of a link between high dose supplementation of vitamin D in helping to prevent or successfully treat Covid-19 and cautioned against over-supplementation of the vitamin, without medical supervision, due to health risks. Scientists concluded that assertions about the benefit of the vitamin in treating the virus are not currently supported by adequate human studies and are based on findings from studies that did not specifically examine this area.

Claims of a link between vitamin D levels and respiratory tract infections were also examined by scientists. Previous studies in this area have found that lower vitamin D status is associated with acute respiratory tract infections however limitations of the findings of these studies were identified. Findings from the majority of studies were based on data gathered from population groups in developing countries and cannot be extrapolated to populations from more developed countries due to external factors. Scientists believe that there is currently no firm link between vitamin D intake and resistance to respiratory tract infections.

Vitamin D toxicity, also called hypervitaminosis D, is a rare but potentially serious condition that occurs when you have excessive amounts of vitamin D in your body.

Vitamin D toxicity is usually caused by taking supplements not diet or sun exposure. Your body regulates the amount of vitamin D produced by sun exposure, and even fortified foods don't containenough vitamin D to worry about.

Too much D can lead to a buildup of calcium in your blood (hypercalcemia), which can cause nausea and vomiting, weakness, and frequent urination. Vitamin D toxicity can also leadto bone pain and kidney stones.

Treatment includes stopping vitamin D intake and restricting your calcium intake. Your doctor might also prescribe intravenous fluids and corticosteroids or bisphosphonates.

Doctors warn against taking anything more thanthe U.S. Recommended Dietary Allowance of 600IUof vitamin D per day.

An adequate level of vitamin D in the body is crucial to our overall health, too little can lead to rickets or the development of osteoporosis but too much can lead to an increase in calcium levels in the blood which could be particularly harmful,Professor Sue Lanham-New, Head of the Department of Nutritional Sciences at the University of Surrey and lead author of the study, said.

Levels of the vitamin in the body can also be supplemented through a nutritionally balanced diet including foods that provide the vitamin, such as fortified foods such as breakfast cereals, and safe sunlight exposure to boost vitamin D status.

Most. people can get enough vitamin D with about ten to 15 minutes of direct sunlight a day.

See the article here:
Doctors: Taking High Doses of Vitamin D Has No Effect on COVID-19 - The Beet

arcognizance.com has added latest research report on Global Osteoporosis Treatment Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, research findings, conclusion, appendix and data source.

With the slowdown in world economic growth, the Osteoporosis Treatment industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Osteoporosis Treatment market size to maintain the average annual growth rate of 15 from XXX million $ in 2014 to XXX million $ in 2019, Report analysts believe that in the next few years, Osteoporosis Treatment market size will be further expanded, we expect that by 2024, The market size of the Osteoporosis Treatment will reach XXX million $.

Request a sample of Osteoporosis Treatment Market report @ https://www.arcognizance.com/enquiry-sample/878965

This Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Definition

Section (2 3): Manufacturer DetailAllergan PlcAmgen, Inc.Actavis Plc.Eli Lilly and CompanyF. Hoffmann La Roche Ltd.GlaxoSmithKline Pharmaceutical Ltd.Merck & Co AGNovartis AGNovo Nordisk A/SPfizer, Inc.Teva Pharmaceuticals Industries Ltd.

Access this report Osteoporosis Treatment Market @ https://arcognizance.com/report/global-osteoporosis-treatment-market-report-2020

Section 4: Region SegmentationNorth America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Section (5 6 7):Product Type SegmentationBisphosphonatesParathyroid Hormone TherapyCalcitoninSelective Estrogen Inhibitors Modulator (SERM)

Industry SegmentationHospitalsClinic

Channel (Direct Sales, Distributor) Segmentation

Section 8: Trend (2019-2024)

Section 9: Product Type Detail

Section 10: Downstream Consumer

Section 11: Cost Structure

Section 12: Conclusion

Buy The Report @ https://www.arcognizance.com/purchase/878965

Table of Content

Chapter One: Osteoporosis Treatment Product Definition

Chapter Two: Global Osteoporosis Treatment Market Manufacturer Share and Market Overview 2.1 Global Manufacturer Osteoporosis Treatment Shipments2.2 Global Manufacturer Osteoporosis Treatment Business Revenue2.3 Global Osteoporosis Treatment Market Overview

Chapter Three: Manufacturer Osteoporosis Treatment Business Introduction

Chapter Four: Global Osteoporosis Treatment Market Segmentation (Region Level)

Chapter Five: Global Osteoporosis Treatment Market Segmentation (Product Type Level)

Chapter Six: Global Osteoporosis Treatment Market Segmentation (Industry Level)

Chapter Seven: Global Osteoporosis Treatment Market Segmentation (Channel Level)

Chapter Eight: Osteoporosis Treatment Market Forecast 2019-2024

Chapter Nine: Osteoporosis Treatment Segmentation Product Type

Chapter Ten: Osteoporosis Treatment Segmentation Industry

Chart and FigureFigure Osteoporosis Treatment Product Picture from Allergan PlcChart 2014-2019 Global Manufacturer Osteoporosis Treatment Shipments (Units)Chart 2014-2019 Global Manufacturer Osteoporosis Treatment Shipments ShareChart 2014-2019 Global Manufacturer Osteoporosis Treatment Business Revenue (Million USD)Chart 2014-2019 Global Manufacturer Osteoporosis Treatment Business Revenue ShareChart Allergan Plc Osteoporosis Treatment Shipments, Price, Revenue and Gross profit 2014-2019Chart Allergan Plc Osteoporosis Treatment Business DistributionChart Allergan Plc Interview Record (Partly)Figure Allergan Plc Osteoporosis Treatment Product PictureChart Allergan Plc Osteoporosis Treatment Business ProfileTable Allergan Plc Osteoporosis Treatment Product SpecificationChart Amgen, Inc. Osteoporosis Treatment Shipments, Price, Revenue and Gross profit 2014-2019Chart Amgen, Inc. Osteoporosis Treatment Business DistributionChart Amgen, Inc. Interview Record (Partly)Figure Amgen, Inc. Osteoporosis Treatment Product PictureChart Amgen, Inc. Osteoporosis Treatment Business OverviewTable Amgen, Inc. Osteoporosis Treatment Product SpecificationChart Actavis Plc. Osteoporosis Treatment Shipments, Price, Revenue and Gross profit 2014-2019Chart Actavis Plc. Osteoporosis Treatment Business DistributionChart Actavis Plc. Interview Record (Partly)Figure Actavis Plc. Osteoporosis Treatment Product PictureChart Actavis Plc. Osteoporosis Treatment Business OverviewTable Actavis Plc. Osteoporosis Treatment Product Specification3.4 Eli Lilly and Company Osteoporosis Treatment Business Introduction continued

Note:

Due to the ongoing COVID-19 pandemic around the world, the figures in the report study represented in the study might differ along with production capacities and other mentioned aspects. Also, note that there is a possibility of a cooldown period after the pandemic that the data might differ as the world economy aims to catch on.

If you have any special requirements, please let us know and we will offer you the report as you want.

Trending Report URLs:

https://www.marketwatch.com/press-release/online-apparel-retailing-market-size-2019-rising-impact-of-covid-19-latest-advancements-developments-and-future-scope-to-2025-2020-05-26

https://www.marketwatch.com/press-release/online-education-market-size-2019-rising-impact-of-covid-19-overview-by-growth-demand-and-future-scope-to-2025-2020-05-26

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448[emailprotected]

Continued here:
Osteoporosis Treatment Market Size, Share, 2020 Emerging-Trends, Services, Applications, Technological-Advancements, Scope, Growth-Analysis,...

Whether youre contemplating using an intrauterine device (IUD) as birth control or to curb the effects of a gynecological issue, you might wonder if the pros outweigh all the cons youve probably heard about. Heres what you need to know about IUDs, according to Ob/Gyn Ashley Brant, DO, MPH.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

Both types work mainly by preventing egg fertilization, but keep in mind that IUDs dont protect against sexually transmitted infections (STIs).

Despite the fact that modern versions are quite safe, IUDs still tend to get a bad rap. Dr. Brant often hears concerns from patients about migration, when the IUD moves through the uterine wall into the abdominal area. Even though it seems like almost everybody knows somebody to whom thats happened, its actually a pretty rare complication, she says. Migration can happen if the uterus is torn, usually by an instrument during IUD insertion; however, these uterine perforations only occur in 0.01 percent of cases.

Other serious complications from IUDs are rare too. Pelvic inflammatory disease (PID) occurs in just 1 percent of women within the first 20 days after insertion and in 0.5 percent in the first three to six months.

Then there are the uncommon side effects women report from the hormonal IUD like weight gain, hair loss, mood changes and acne. As of now, there isnt enough research to support or refute a definitive link between the two, Dr. Brant says. In fact, the low level of progestin released one-fifth of the amount found in combination birth control pills is tolerated well by the majority of women.

Dr. Brant asks her patients these 3 questions to help them come to a decision thats right for them:

Placing an IUD usually takes less than five minutes. To begin the insertion process, the doctor or nurse will likely feel your uterus to see which way it might be tipping. A speculum is placed, just like youd have for a Pap smear, and the cervix is washed off with soap.

You can expect to experience cramping three times, but only for a few seconds each time, says Dr. Brant.

Read more:
Do the Benefits of an IUD Outweigh the Potential Side Effects? - Health Essentials from Cleveland Clinic

RESEARCH TRIANGLE PARK Theres a new biotech company setting up shop in the Triangle, and its flush with cash and headed up by some big names in the industry.

MeetKriya Therapeutics the brainchild of Dr. Shankar Ramaswamy, former chief business officer for Axovant Gene Therapies; Fraser Wright, co-founder of Sparks Therapeutics; and Roger Jeffs, the former United Therapeutics CEO who has deep rootsinNorth Carolina.

Launched in 2019, the biotech startup has dual headquarters in Durham and Palo Alto, California, and is billing itself as a next-generation gene therapy company focused on designing and developing treatments for highly prevalent and severe chronic conditions, like diabetes and obesity.

Earlier this month, it arrived in a big way after securing $80.5 million in Series A financing during a pandemic.

Its never easy. But itsa really significant pool of capital for us so were thankful to have been able to get it done,Ramaswamy, Kriyas CEO, told NC Biotech in a video interview this week.[Our] investors have a very long term vision of what a next generation gene therapy company could look like, and were very supportive building towards that vision.

Fraser Wright, PhDScientific Co-Founder and Chief Scientific Advisor; Shankar Ramaswamy, MDCo-Founder, Chairman, and CEO; and Nachi Gupta, MD, PhDChief of Staff.

Among the investors: QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures (associated with Sutter Hill Ventures), Narya Capital, Amplo,Paul Manning, andAsia Alpha. The round followed an initial seed financing led by Transhuman Capital late last year.

Itsis amilestone for the company andsets us up for success to goout and execute on the things that we really want to get done.

Ramaswamy says the company is now ready to scale, and is focused on building out its teams on both coasts.

We expect to grow very quickly both here in the Bay Area and in North Carolina, he said, emphasizing the Triangles importance as its manufacturing hub. That could be dozens of employees [here] in the not so distant future, if not larger over time.

How it will work: co-founders Ramaswamy and Wright will be based in the Bay area along with finance operations and early-stage research.

Meanwhile, in Durham, co-founder Jeffs will lead a team focused on development and manufacturing. It will include Britt Petty, AveXis former head of global manufacturing and Melissa Rhodes, former chief development officer at Altavant Sciences; and Mitch Lower, another Avexis veteran.

I dont view North Carolina as a satellite office.Thats where well be building our internal manufacturing infrastructure to solve for one of the key bottlenecks in gene therapy,which is manufacturing capacity and quality, saidRamaswamy.

Theres a very strong pool of talent in North Carolina, especially in biologics manufacturing. And [our team] has a very strong track record and history of success with biologics manufacturing, and strong experience there as well. So we think its a great place to be, given the past couple of decades, where there have been so many successful products actually manufactured in North Carolina.

Already, Kriyahas a number of gene therapies in the pipeline.

Among them: KT-A112, an investigational gene therapy administered by intramuscular injection that delivers the genes to produce insulin and glucokinase for type 1 and type 2 diabetes;KT-A522, an investigational gene therapy administered by salivary gland injection that delivers the gene to produce a glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes and severe obesity; andKT-A83, an investigational gene therapy administered by intrapancreatic injection that delivers the gene to produce modified insulin growth factor 1 (IGF-1) for type 1 diabetes.

The team is currently set up in a temporary office in Durham, but plans to move intoamore permanent space somewhere in the Research Triangle in the near future.

Kriya is building a leading team and cutting-edge infrastructure to engineer best-in-class gene therapies for severe chronic conditions and accelerate their advancement into human clinical trials, saidJeffs, its vice chairman. Through its R&D laboratory capabilities in the Bay Area and in-house process development and manufacturing infrastructure inResearch Triangle Park, I believe that Kriya will be uniquely positioned to become a leader in the gene therapy field.

(c) North Carolina Biotechnology Center

Durhams Kriya Therapuetics lands $80M to advance gene therapies for diabetes, severe obesity

Read this article:
Bicoastal startup Kriya Therapeutics to grow gene therapy manufacturing in NC - WRAL Tech Wire

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, and Immunochinaa company dedicated to innovative gene and cellular technology today announced that they have formed a research and development collaboration to develop allogeneic CAR-T therapy for cancer.

Under this partnership, both companies will combine EdiGenes expertise in genome editing and allogeneic T-cell process with Immunochinas expertise in innovative CAR-T technology to develop potentially best-in-class allogeneic CAR-T therapeutics. Terms are not disclosed.

"EdiGene is a leading gene-editing company with cutting edge technology platform. It is our great pleasure to work with this team," said Ting He, Ph.D.founder and CEO of Immunochina, "Make the Incurable Curable, which is Immunochinas vision. We have accumulated considerable experience in late-stage hematological malignancies, with two IND approvals. Although a number of break throughs have been made by autologous T cells lately, allogeneic T cells could also play an important role in the future. The cooperation is a big step for both teams, and I believe we will make exciting discoveries together."

We are excited to collaborate with Immunochina, one of the leading clinical-stage CAR-T companies, said Dong Wei, Ph.D.CEO of EdiGene, We believe that allogeneic T-cell therapeutics has tremendous potential, by offering innovative T-cell therapies off the shelf with more effective quality control and lower cost. By combining the expertise of EdiGene and Immunochina, we will be well positioned to develop such therapeutics and advance to clinics, one step closer to help the cancer patients in need.

About EdiGene, Inc

EdiGene is a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA. More information can be found at http://www.edigene.com.

About Immunochina

Immunochina is committed to the application of innovative gene and cellular technology for treatment of lethal diseases. The company owns integrated CAR-T platform, including core technologies such as large-scale viral vector production and primary immune cell processing. The pipeline includes several CAR-T candidates for treatment of advanced cancer, with two IND approvals. Founded in 2015, Immunochina is headquartered in Beijing. More information can be found at http://www.immunochina.com

Originally posted here:
EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer - Business Wire

Pune, May 27, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during the forecast period. The growing R&D investment by key players for the development of innovative regenerative therapies can be a vital factor enabling the growth of the market during the forecast period, states Fortune Business Insights in a report, titled Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 2026 the market size stood at USD 23,841.5 Million in 2018. The growing organ transplantation surgeries will spur opportunities for the market during the forecast period.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Market Driver:

Escalating Cases of Genetic Disorders to Augment Growth

The increasing prevalence of chronic disorders can be an essential factor enabling the growth of the market. Similarly, the growing incidence of genetic disorders will fuel demand for the market. The growing investment in R&D activities by major market players will have a positive impact on the regenerative medicine market growth during the forecast period. For instance, in March 2018, SanBio Group, a leader in regenerative medicine and therapies for neurological disorders announced that it has made a deal with Hitachi Chemical Advanced Therapeutics Solutions, LLC, a cell manufacturing company for the development and manufacturing of innovative regenerative medicines.

Furthermore, the rising cases of neurological disorders will influence the healthy growth of the market. The growing healthcare expenditure in developed and developing countries will boost the market in the forthcoming years. The ongoing clinical trials and robust pipeline products in stem cell andgene therapy will contribute tremendously to the growth of the market. The rising utilization of skin substitutes, grafts, bone matrix, and other tissue-engineered regenerative medicine in orthopedic and neurosurgical applications will augment the growth of the market.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Regional Analysis:

Development of Novel Therapies to Favor Growth in North America

The market in North America generated a revenue of USD 9,128.2 million in 2018 and is predicted to grow rapidly during the forecast period owing to the presence of major pharmaceutical companies. The growing launch of novel therapeutics and the availability of advanced technologies along with clinical trials will support growth in North America. Asia Pacific is expected to witness a high growth rate during the forecast period owing to the

developing healthcare infrastructure and facilities. The increasing stem cell research in developing countries such as India, Japan China will contribute positively to the growth of the market. For instance, In April 2013, the Japan Ministry of Health, Labor, and Welfare approved Regenerative Medicine law. The growing number of clinical developments of regenerative and cell-based therapies will drive the market in the region. The increasing government initiatives for human embryonic stem cell research and development will further encourage growth in the region. The surge in geriatric patients, the evolving lifestyle of people, and the growing need for novel therapies are factors likely to aid the expansion of the market in Asia Pacific.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

Key Development:

2018: Novartis announced that it has received EUs approval for one-time gene therapy Luxturna, to restore vision in people with rare and genetically-associated retinal disease.

List of the Key Companies Operating in the Regenerative Medicine Market are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

Have a Look at Related Reports:

Gene Therapy Market Size, Share and Global Trend By Disease Indication(Cancer, Genetic disorders, Cardiovascular diseases, Ophthalmology, Neurological conditions) By Type of Vectors (Viral vectors, Non-viral vectors), By Type of Cells(Somatic cells, Germline cells) and Geography Forecast till 2026

Induced Pluripotent Stem Cells Market Size, Share and Global Trend By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education & research institutes, Biotechnological companies) and Geography Forecast till 2026

Platelet Rich Plasma Market Size, Share And Global Trend By Origin (Allogeneic, Autologous, Homologous), By Type (Pure PRP, Leukocyte rich PRP, Leukocyte rich fibrin), By Application (Orthopaedic surgery, Cosmetic surgery, General surgery, Neurosurgery, Others), And Geography Forecast Till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Continue reading here:
Regenerative Medicine Market to Exhibit a CAGR of 26.1% by 2026; Rising Prevalence of Genetic Disorders to Fuel Demand, states Fortune Business...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan. The CGCPII has been operational since January 2020.

The CGCPII is an expansion of the Center for Gene and Cell Processing (CGCP), which was established in 2014 and designed specifically for the safe, efficient manufacture of gene and cell therapy products. Both facilities have received ISO 9001 certification. The CGCPII provides additional capacity for Good Manufacturing Practice (GMP) viral vector production, process development, aseptic filling, and quality-testing facilities, as well as room for future expansion.

With the addition of the CGCPII, Takara Bio is able to accommodate the growing demand for gene and cell therapies and will continue to enhance its services for biopharmaceuticals and regenerative medicine products under GMP and Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP).

"Takara Bio is excited to increase our capacity to provide even more support to customers worldwide in the development of their regenerative medicine products. We have a history of developing products like RetroNectin reagent for regenerative medicine research, and we are building on that history with our expanded facility and service offerings," said Junichi Mineno, Chief Operating Officer, Takara Bio Inc.

With our state-of-the-art GMP manufacturing facilities in Japan and Europe, Takara Bio provides services for viral vector production, cell processing, clinical-grade human embryonic stem cell line derivation, quality testing, and cell banking. These gene and cell therapy manufacturing services, carried out by a global team of seasoned experts, provide support throughout the entire process of developing vital regenerative medicine products.

About Takara Bio

Takara Bio USA, Inc. (TBUSA) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

See the article here:
Takara Bio Announces the Completion of a New GMP Facility for Manufacturing Gene and Cell Therapy Products - Business Wire